Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD.

Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19.

2.

MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.

Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD.

PLoS One. 2016 Nov 15;11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016.

3.

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Am J Surg Pathol. 2016 Nov;40(11):1439-1456.

PMID:
27635949
5.

Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.

Kim Y, Jeon J, Mejia S, Yao CQ, Ignatchenko V, Nyalwidhe JO, Gramolini AO, Lance RS, Troyer DA, Drake RR, Boutros PC, Semmes OJ, Kislinger T.

Nat Commun. 2016 Jun 28;7:11906. doi: 10.1038/ncomms11906.

6.

Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L.

Prostate. 2016 Nov;76(15):1409-19. doi: 10.1002/pros.23225. Epub 2016 Jun 21.

7.

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3.

8.

Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis.

Wang Y, Jadhav RR, Liu J, Wilson D, Chen Y, Thompson IM, Troyer DA, Hernandez J, Shi H, Leach RJ, Huang TH, Jin VX.

Sci Rep. 2016 Feb 29;6:22051. doi: 10.1038/srep22051.

9.

Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression.

Philley JV, Kannan A, Qin W, Sauter ER, Ikebe M, Hertweck KL, Troyer DA, Semmes OJ, Dasgupta S.

J Cell Physiol. 2016 Jun;231(6):1364-74. doi: 10.1002/jcp.25240. Epub 2015 Nov 24.

10.

Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.

Yang L, Dutta SM, Troyer DA, Lin JB, Lance RA, Nyalwidhe JO, Drake RR, Semmes OJ.

Oncotarget. 2015 Dec 22;6(41):43743-58. doi: 10.18632/oncotarget.6193.

11.

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.

12.

Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.

Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK.

PLoS One. 2015 Jul 14;10(7):e0132343. doi: 10.1371/journal.pone.0132343. eCollection 2015.

13.

A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.

Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA.

Prostate. 2015 Aug 1;75(11):1206-15. doi: 10.1002/pros.23003. Epub 2015 May 4.

14.

MDA-9/Syntenin regulates differentiation and angiogenesis programs in head and neck squamous cell carcinoma.

Oyesanya RA, Bhatia S, Menezes ME, Dumur CI, Singh KP, Bae S, Troyer DA, Wells RB, Sauter ER, Sidransky D, Fisher PB, Semmes OJ, Dasgupta S.

Oncoscience. 2014 Sep 18;1(11):725-737. eCollection 2014.

15.

MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays.

Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, Haab BB, Drake RR.

PLoS One. 2014 Sep 3;9(9):e106255. doi: 10.1371/journal.pone.0106255. eCollection 2014.

16.

Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.

Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI.

J Urol. 2014 Oct;192(4):1081-7. doi: 10.1016/j.juro.2014.04.013. Epub 2014 Apr 18.

17.

MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma.

Jones EE, Powers TW, Neely BA, Cazares LH, Troyer DA, Parker AS, Drake RR.

Proteomics. 2014 Apr;14(7-8):924-35. doi: 10.1002/pmic.201300434. Epub 2014 Mar 3.

18.

Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.

Nyalwidhe JO, Betesh LR, Powers TW, Jones EE, White KY, Burch TC, Brooks J, Watson MT, Lance RS, Troyer DA, Semmes OJ, Mehta A, Drake RR.

Proteomics Clin Appl. 2013 Oct;7(9-10):677-89. doi: 10.1002/prca.201200134. Epub 2013 Sep 13.

19.

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, Semmes OJ, Troyer DA, Lance RS, Kislinger T, Drake RR.

Proteomics. 2013 May;13(10-11):1667-1671. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.

20.

Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.

Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T.

Mol Cell Proteomics. 2012 Dec;11(12):1870-84. doi: 10.1074/mcp.M112.017889. Epub 2012 Sep 17.

21.

Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies.

Brown MV, McDunn JE, Gunst PR, Smith EM, Milburn MV, Troyer DA, Lawton KA.

Genome Med. 2012 Apr 30;4(4):33.

22.

Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.

Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, Troyer DA, Alessandro R, Semmes OJ, Kislinger T, Drake RR, Medin JA.

J Proteome Res. 2012 Apr 6;11(4):2386-96. doi: 10.1021/pr2011236. Epub 2012 Feb 29.

23.
24.

Molecular pathology of prostate cancer.

Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA.

Cancer Biomark. 2010;9(1-6):441-59. doi: 10.3233/CBM-2011-0181. Review.

PMID:
22112489
25.

Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer.

Lance RS, Drake RR, Troyer DA.

Expert Rev Anticancer Ther. 2011 Sep;11(9):1341-3. doi: 10.1586/era.11.134.

PMID:
21929308
26.

Using boronolectin in MALDI-MS imaging for the histological analysis of cancer tissue expressing the sialyl Lewis X antigen.

Dai C, Cazares LH, Wang L, Chu Y, Wang SL, Troyer DA, Semmes OJ, Drake RR, Wang B.

Chem Commun (Camb). 2011 Oct 7;47(37):10338-40. doi: 10.1039/c1cc11814e. Epub 2011 Aug 19.

PMID:
21853197
27.

MALDI tissue imaging: from biomarker discovery to clinical applications.

Cazares LH, Troyer DA, Wang B, Drake RR, Semmes OJ.

Anal Bioanal Chem. 2011 Jul;401(1):17-27. doi: 10.1007/s00216-011-5003-6. Epub 2011 May 4. Review.

28.

Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies.

Troyer DA, Lucia MS, de Bruïne AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2717-22. doi: 10.1158/1055-9965.EPI-09-0068. Epub 2009 Sep 15.

29.

The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.

Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA, Pikarsky E, Karin M, Farber JM.

PLoS One. 2009 Aug 19;4(8):e6695. doi: 10.1371/journal.pone.0006695.

30.

Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis.

Beuten J, Garcia D, Brand TC, He X, Balic I, Canby-Hagino E, Troyer DA, Baillargeon J, Hernandez J, Thompson IM, Leach RJ, Naylor SL.

J Urol. 2009 Oct;182(4):1614-20. doi: 10.1016/j.juro.2009.06.016. Epub 2009 Aug 15.

PMID:
19683737
31.

Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.

Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, Yeh IT, Troyer DA, Olumi AF, Kumar AP.

Clin Cancer Res. 2009 Mar 1;15(5):1601-11. doi: 10.1158/1078-0432.CCR-08-1389. Epub 2009 Feb 17.

32.

Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.

Mubiru JN, Hubbard GB, Dick EJ Jr, Furman J, Troyer DA, Rogers J.

Prostate. 2008 Oct 1;68(14):1546-54. doi: 10.1002/pros.20814.

33.

Characterization of PacMetUT1, a recently isolated human prostate cancer cell line.

Troyer DA, Tang Y, Bedolla R, Adhvaryu SG, Thompson IM, Abboud-Werner S, Sun LZ, Friedrichs WE, deGraffenried LA.

Prostate. 2008 Jun 1;68(8):883-92. doi: 10.1002/pros.20758.

PMID:
18361412
34.

Association of polymorphisms in TGFB1 and prostate cancer prognosis.

Brand TC, Bermejo C, Canby-Hagino E, Troyer DA, Baillargeon J, Thompson IM, Leach RJ, Naylor SL.

J Urol. 2008 Feb;179(2):754-8. Epub 2007 Dec 20.

PMID:
18082198
35.

Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.

Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, Troyer DA, Kumar AP.

Neoplasia. 2007 Nov;9(11):893-9.

36.

Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.

Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, Ankerst DP, Thompson IM, Leach RJ, Parekh DJ.

Urology. 2007 Oct;70(4):748-52.

PMID:
17991549
37.

Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.

Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ.

Clin Cancer Res. 2007 Oct 1;13(19):5959-64.

38.

A preliminary study of the baboon prostate pathophysiology.

Mubiru JN, Hubbard GB, Dick EJ Jr, Butler SD, Valente AJ, Troyer DA, Rogers J.

Prostate. 2007 Sep 15;67(13):1421-31.

PMID:
17639509
39.

Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.

Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM.

Clin Cancer Res. 2007 Jul 1;13(13):3860-7.

40.
41.

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.

Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, Troyer DA, Leach RJ, Thompson IM.

Urology. 2006 Dec;68(6):1152-5.

PMID:
17169636
42.

Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization.

Vijayakumar S, Hall DC, Reveles XT, Troyer DA, Thompson IM, Garcia D, Xiang R, Leach RJ, Johnson-Pais TL, Naylor SL.

Cancer Res. 2006 Apr 15;66(8):4055-64.

43.

The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial.

Hernáandez J, Syed S, Weiss G, Fernandes G, von Merveldt D, Troyer DA, Basler JW, Thompson IM Jr.

J Urol. 2005 Aug;174(2):519-22.

PMID:
16006884
44.
45.

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.

Endocr Relat Cancer. 2005 Mar;12(1):119-34.

PMID:
15788644
46.

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.

Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS.

Prostate. 2005 May 15;63(3):231-9.

PMID:
15538746
47.

Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.

Troyer DA, Mubiru J, Leach RJ, Naylor SL.

Dis Markers. 2004;20(2):117-28. Review.

48.

Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.

Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM.

Cancer Res. 2004 Aug 1;64(15):5232-6.

49.

Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer.

Mubiru JN, Shen-Ong GL, Valente AJ, Troyer DA.

Gene. 2004 Feb 18;327(1):89-98.

PMID:
14960364
50.

5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.

Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS, Lazier CB.

J Urol. 2003 Nov;170(5):2019-25.

PMID:
14532845

Supplemental Content

Loading ...
Support Center